The company expects net product revenues from sales of zynlonta to be approximately $15.8M for the third quarter ended September 30, with cash and cash equivalents totaling $234.7M as of September 30, 2025. Giving effect to the estimated net proceeds from the PIPE financing of approximately $57.6M, the company would have had approximately $292.3M of cash and cash equivalents as of that date.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT: